These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 18374623)

  • 21. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics.
    Dimberg LY; Anderson CK; Camidge R; Behbakht K; Thorburn A; Ford HL
    Oncogene; 2013 Mar; 32(11):1341-50. PubMed ID: 22580613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TRAIL and targeting cancer cells: between promises and obstacles.
    Limami Y; Pinon A; Riaz A; Simon A
    Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(6):33-8. PubMed ID: 26518894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting miRNAs associated with surface expression of death receptors to modulate TRAIL resistance in breast cancer.
    Zhu J; Zhou Q; Tan S
    Cancer Lett; 2016 Dec; 383(2):154-160. PubMed ID: 27693456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL).
    Fulda S
    Adv Exp Med Biol; 2014; 818():167-80. PubMed ID: 25001536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TRAIL-based therapeutic approaches for the treatment of pediatric malignancies.
    Gasparini C; Vecchi Brumatti L; Monasta L; Zauli G
    Curr Med Chem; 2013; 20(17):2254-71. PubMed ID: 23458616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative.
    Kumazaki M; Shinohara H; Taniguchi K; Ueda H; Nishi M; Ryo A; Akao Y
    Oncotarget; 2015 Sep; 6(28):25828-42. PubMed ID: 26304927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TRAIL: a sword for killing tumors.
    Wang S
    Curr Med Chem; 2010; 17(29):3309-17. PubMed ID: 20712573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
    Wang S
    Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis.
    Secchiero P; Zauli G
    Curr Opin Hematol; 2008 Jan; 15(1):42-8. PubMed ID: 18043245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TRAIL death receptors and cancer therapeutics.
    Huang Y; Sheikh MS
    Toxicol Appl Pharmacol; 2007 Nov; 224(3):284-9. PubMed ID: 17240413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytotoxic Efficacy and Resistance Mechanism of a TRAIL and VEGFA-Peptide Fusion Protein in Colorectal Cancer Models.
    Kopczynski M; Statkiewicz M; Cybulska M; Kuklinska U; Unrug-Bielawska K; Sandowska-Markiewicz Z; Grochowska A; Gajewska M; Kulecka M; Ostrowski J; Mikula M
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33808900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overcoming TRAIL Resistance for Glioblastoma Treatment.
    Deng L; Zhai X; Liang P; Cui H
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33919846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
    Rowinsky EK
    J Clin Oncol; 2005 Dec; 23(36):9394-407. PubMed ID: 16361639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PRAME/EZH2-mediated regulation of TRAIL: a new target for cancer therapy.
    De Carvalho DD; Mello BP; Pereira WO; Amarante-Mendes GP
    Curr Mol Med; 2013 Feb; 13(2):296-304. PubMed ID: 23228130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.
    Ehrenschwender M; Bittner S; Seibold K; Wajant H
    Cell Death Dis; 2014 Dec; 5(12):e1570. PubMed ID: 25501831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myc tagging along the TRAIL to death receptor 5.
    Sheikh MS
    Cell Cycle; 2004 Jul; 3(7):920-2. PubMed ID: 15254425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy.
    Van Geelen CM; de Vries EG; de Jong S
    Drug Resist Updat; 2004 Dec; 7(6):345-58. PubMed ID: 15790545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The long and winding road to cancer treatment: the TRAIL system.
    Palacios C; Yerbes R; Sanchez-Perez T; Martin-Perez R; Cano-Gonzalez A; Lopez-Rivas A
    Curr Pharm Des; 2014; 20(17):2819-33. PubMed ID: 23944369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The TRAIL of oncogenes to apoptosis.
    Oikonomou E; Pintzas A
    Biofactors; 2013; 39(4):343-54. PubMed ID: 23813857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
    Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
    Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.